Ortho Clinical Diagnostics Holdings PLC Stock News

Ortho Clinical Diagnostics (NASDAQ:OCDX) and StageZero Life Sciences (OTCMKTS:SZLSF) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk and analyst recommendations. Valuation and Earnings This table compares Ortho Clinical Diagnostics and StageZero Life Sciences top-line []

Man Group plc raised its position in Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) by 70.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,288 shares of the companys stock after acquiring an additional 27,471 shares during the quarter. []

Man Group plc lifted its position in Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) by 70.8% in the second quarter, Holdings Channel.com reports. The institutional investor owned 66,288 shares of the companys stock after buying an additional 27,471 shares during the period. Man Group plcs holdings in Ortho Clinical Diagnostics were worth $1,419,000 at the end []

Ortho Clinical Diagnostics Holdings plc (OCDX) CEO Chris Smith on Q3 2021 Results - Earnings Call Transcript

RARITAN, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it will re

RARITAN, N.J., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world's largest pure-play in vitro diagnostics companies, today

RARITAN, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world's largest pure-play in vitro diagnostics companies, today

RARITAN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world's largest pure-play in vitro diagnostics companies, today

RARITAN, N.J., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced tha

Ortho Clinical Diagnostics Holdings plc (OCDX) CEO Chris Smith on Q2 2021 Results - Earnings Call Transcript

Strong Revenue Growth Drives Financial Results

RARITAN, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it will report results

RARITAN, N.J., July 22, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its VITROS® Immunodiagn

The FDA has granted Emergency Use Authorization (EUA) to Ortho Clinical Diagnostics' (NASDAQ: OCDX) VITROS Anti-SARS-CoV-2 IgG Quantitative Test. The company says it the first quantitative COVID-1

- Ortho's new VITROS® Anti-SARS-CoV-2 IgG Quantitative Test targets the S1 spike protein and is calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which gives clinici